[361]
Thyroid Cancer Rates and I Doses From Nevada Atmospheric Nuclear ...
[93,8 KB]
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[362]
Medical Diagnostic X Rays and Thyroid Cancer
From [jncicancerspectrum.oxfordjournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[363]
History of Thyroid Diseases and Subsequent Thyroid Cancer Risk1
[932,5 KB]
From [cebp.aacrjournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[364]
Sonographic Screening for Thyroid Cancer in Females Undergoing ...
From [www.ajronline.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[365]
Cutaneous manifestations of thyroid cancer: a report of four cases ...
[812,3 KB]
From [jcp.bmjjournals.com] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[366]
Editorial: Challenging Dogma in Thyroid Cancer Molecular Genetics ...
[64,4 KB]
From [jcem.endojournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[367]
Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid ...
[96,5 KB]
From [jcem.endojournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[368]
Perspective: Lessons Learned from Molecular Genetic Studies of ...
[74,2 KB]
From [endo.endojournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[369]
High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic ...
[118,9 KB]
From [cancerres.aacrjournals.org] Last viewed: 07.09.2006
TBILISI STATE MEDICAL UNIVERSITY
ANNALS OF BIOMEDICAL RESEARCH AND EDUCATION
2003 April/June, Volume 3, Issue 2
The Changes of pH and Partial Pressure of
Oxygen in Blood at Chronic Heart Failure
Nino Mamamtavrishvili*, Giorgi Red'ko**, Gulnara Tabidze*,
Marina Iakobashvili*
* Scientific-Research Institute of Cardiology, Tbilisi, Georgia,
**TSMU Scientific-Research Institute of Experimental Medicine, Tbilisi, Georgia
Abstract
Disorders in myocardium metabolism taking place at heart failure are connected with reduced blood supply
and promote decrease of ATP production, breaking of oxygen consumption, increase of lactate and hydrogen
ions' production. In this connection study of changes of partial pressure of oxygen ions occurring in blood of
patients with systolic and diastolic forms of heart failure seems to be of great interest. On the basis of obtained
results ...
[370]
Thyroid Cancer since the Chernobyl Accident: a Hypothesis
[19,4 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[371]
Medullary and Non-medullary Thyroid Cancer in a Family
[20,1 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[372]
Expression of Cholecystokinin-B/Gastrin Receptors in Medullary ...
[20,2 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[373]
Clinical Recurrence of Papillary Thyroid Cancer in the Remnant Lobe
[20,9 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[374]
Radiation and Thyroid Cancer
[18,5 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[375]
Differentiated Thyroid Cancer Presenting as Distant Metastases
[19,5 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[376]
Thyroid Cancer after X-ray Treatment of Benign Disorders of the ...
[21,0 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[377]
Clinico-pathological Features of Thyroid Cancer as Observed in ...
[21,2 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[378]
Thyroid Cancer: A Unique Human Neoplasm
[19,9 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[379]
Total Thyroidectomy for Differentiated Thyroid Cancer: Primary ...
[20,7 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[380]
Radiogenic initiation of thyroid cancer: a common cellular event
[20,7 KB]
From [taylorandfrancis.metapress.com] Last viewed: 07.09.2006
European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: orphandrugs@emea.eu.int www.emea.eu.int
EMEA 2004 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged
Document Date: London, 5 November 2004
EMEA/COMP/136/04
COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS
PUBLIC SUMMARY OF
POSITIVE OPINION FOR ORPHAN DESIGNATION
OF
2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
for the treatment of anaplastic thyroid cancer
On 14 April 2004, orphan designation (EU/3/04/195) was granted by the European Commission to
David Chaplin, United Kingdom, for 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl) ethenyl]-phenol
(combretastatin A4 phosphate) for ...
[381]
A case of dermatomyositis associated with papillary cancer of the ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[382]
Thyroid cancer with a high 123 I-NaI ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[383]
Epidemiological Evidence for a Link Between Postpartum Thyroiditis ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[384]
Positive thyroid cancer scintigraphy using technetium-99m ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[385]
Detection of metastatic medullary thyroid cancer with <Superscript ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[386]
Multiple haemorrhagic brain metastases from papillary thyroid cancer
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[387]
Thyroid cancer pooled analysis from 14 case–control studies: what ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[388]
Thyroid cancer in children and adolescents
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[389]
Percutaneous ethanol injection therapy for patients with ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
National Standards
for Thyroid
Cancer Services
2005
Page 2
G/356/04-05
January
Typeset in 12pt
ISBN 0 7504 3654 9
CMK-22-02-014
© Crown copyright 2005
Page 3
Contents
1.
Introduction to Cancer Standards
1
2.
Methodology
2
3.
Format
3
4.
Introduction to Thyroid Cancer Standards
4
Topic: Organisation
6
Topic: Patient-centred Care
10
Topic: The MultiDisciplinary Team
14
Topic: Initial Referral and Times to Treatment
18
Topic: Diagnosis, Staging and Treatment
20
Page 4
Page 5
1
1.
INTRODUCTION TO THE CANCER STANDARDS
1.1 These Cancer Standards replace the previous Minimum Standards issued
in 2000 and continue the process of regularly ...
[390]
Resection and Reconstruction of the Airway in Patients with ...
[19,7 KB]
From [www.springerlink.com] Last viewed: 07.09.2006
Found 1335 documents
Page 13 of 45 Pages:
<< < 8 9 10 11 12 13 14 15 16 17 18 > >>
cancers
homepage
last week